Keyword: Acadia Pharmaceuticals
Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.
Months after a late-stage loss in schizophrenia, Acadia's Nuplazid is showing promise at improving the negative symptoms of the disease.
Acadia was stung hard after its schizophrenia hopes for Nuplazid fell flat back in late July. Fortunately, dementia-related psychosis shows promise.
With psychosis med Nuplazid facing a DOJ probe and schizophrenia flop, Acadia hopes a new round of TV ads will help court more patients.
Acadia’s Nuplazid is under the gun after prosecutors launched a marketing probe in March. Now the drug has to cope with a trial flop in schizophrenia.